Cryopreserved MLPSCs for Refractory Chronic GvHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic Graft versus Host Disease (cGvHD) are inadequate, particularly for patients who are refractory to steroid immunosuppressants and biologic therapies, with a need for new therapeutic options that can effectively manage the autoimmune and fibrotic features of the condition.
Innovation Solution
Administration of culture-expanded mesenchymal lineage precursor or stem cells (MLPSCs) that have been cryopreserved and thawed, which can be used as an 'off-the-shelf' product without the need for HLA matching, expressing TNFR1 and administered intravenously to achieve a partial or complete response in cGvHD patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional steroid immunosuppressants and biologic therapies are used to treat cGvHD, then some patients experience initial response, but patients become refractory and require additional immunosuppression which increases toxicity without improving efficacy
Solution Approach 1:
The patent introduces a third-party allogeneic MSC product as an intermediary therapeutic agent that mediates immune modulation without requiring HLA matching. These MSCs act as a bridge between the patient's immune system and the desired therapeutic outcome, providing immunosuppressive effects through paracrine mechanisms and immune cell interaction rather than direct cytotoxicity, thereby avoiding the cumulative toxicity of conventional immunosuppressants
Solution Approach 2:
The patent changes the fundamental parameter of immune suppression from pharmacological inhibition (drugs) to biological modulation (MSCs). By altering the mechanism from chemical immunosuppression to cellular immunomodulation, the treatment achieves therapeutic effects while avoiding the dose-dependent toxicity accumulation that occurs with conventional immunosuppressants
2Reliability
If HLA-matched allogeneic stem cells are used for treatment, then graft rejection is reduced, but the complexity and time required for matching increases
Solution Approach 1:
The patent creates a universal MSC product that can be used across multiple patients without requiring individualized HLA matching. The MSCs possess broad immunomodulatory capabilities that function effectively regardless of HLA compatibility, making the therapy universally applicable to cGvHD patients while eliminating the complex matching process
Solution Approach 2:
The patent extracts and eliminates the HLA matching requirement from the treatment process entirely. By selecting MSCs from bone marrow or adipose tissue that inherently possess low immunogenicity and broad compatibility, the patent removes the matching step while maintaining graft acceptance through the cells' natural immunomodulatory properties
3Quantity of substance
If culture expansion is performed to increase cell dosage, then therapeutic effect is enhanced, but risk of genetic abnormalities and loss of differentiation potential increases
Solution Approach 1:
The patent performs preliminary quality control measures during the culture expansion process, including regular monitoring of passage number, genetic stability markers, and differentiation potential. By establishing predetermined limits for expansion passages and implementing quality checkpoints before administration, the patent ensures that cells maintain their therapeutic properties while achieving sufficient dosage
Solution Approach 2:
The patent optimizes culture conditions by changing physical and chemical parameters such as oxygen tension, growth factor concentrations, and substrate composition. These parameter adjustments promote healthy cell proliferation while minimizing genomic instability and differentiation, allowing expansion to therapeutic doses without compromising cell quality
4Ease of operation
If cryopreservation is used to create off-the-shelf product, then availability and ease of administration is improved, but cell viability and function may be compromised
Solution Approach 1:
The patent utilizes controlled phase transition from liquid to solid state through cryopreservation. By slowly freezing cells in controlled conditions with appropriate cryoprotectants, the patent transforms the cell suspension into a stable frozen state that can be stored and transported, then reverses the process during thawing to restore cell viability and function for immediate administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment results in a partial or complete response characterized by reductions in various symptom scores, including skin, mouth, eye, gastrointestinal, liver, lung, and joint scores, indicating significant clinical improvement in cGvHD patients, even those who have not responded to conventional therapies.
Implementation Method 1
administration of culture expanded mesenchymal lineage precursor or stem cell that have been cryopreserved and thawed
Data Source
AI summary
The present disclosure relates to methods for treating or preventing chronic graft versus host disease in a subject in need thereof, the method comprising administering to the subject a composition comprising culture expanded mesenchymal lineage precursor or stem cells (MLPSCs).